QCDx Secures $7M to Revolutionize Early Cancer Diagnosis with Next-Generation Liquid Biopsy Technology

QCDx is thrilled to announce a major milestone in our journey to revolutionize cancer diagnostics, having successfully raised $7,000,000 in our latest funding round. This significant investment reinforces our mission to deliver a next-generation liquid biopsy solution for precision diagnosis, enabling sensitive and specific detection of rare cells that mark the early onset and progression of cancer. At the heart of our innovative approach is our proprietary RareScope™ platform, meticulously engineered to analyze intact cell suspensions with unmatched sensitivity across the epithelial to mesenchymal spectrum of Circulating Tumor Cells (CTCs). By detecting even the most elusive CTC phenotypes, RareScope™ not only provides deep characterization for biomarkers associated with targeted therapy and immunotherapy, but also facilitates the isolation of these cells for further molecular analysis, thereby offering invaluable insights into individualized treatment options. The newly secured funding will be pivotal in accelerating the refinement and clinical validation of our liquid biopsy technology. With these resources, QCDx is poised to expand its research and development efforts, strengthen its analytical capabilities, and forge essential partnerships within the healthcare ecosystem. Furthermore, the investment will propel our plans to explore the ex vivo evaluation of bioactive substances on CTCs, such as cancer drugs, to optimize drug selection and maximize treatment efficacy before patient administration. This endeavor underscores our commitment to addressing the unmet needs in early cancer diagnosis, treatment monitoring, and disease recurrence surveillance. As we continue to push the boundaries of precision medicine, we remain dedicated to making transformative impacts in cancer care and improving patient outcomes worldwide.